<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872947</url>
  </required_header>
  <id_info>
    <org_study_id>950P1V02</org_study_id>
    <nct_id>NCT03872947</nct_id>
  </id_info>
  <brief_title>A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Toray Industries, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to establish the safety and the recommended dose of TRK-950&#xD;
      in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab&#xD;
      / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab,&#xD;
      Gemcitabine / Carboplatin / Bevacizumab, Topotecan, and Pegylated liposomal doxorubicin (PLD)&#xD;
      for selected advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, Phase 1b study evaluating TRK-950 in combination with 1) FOLFIRI&#xD;
      or 2) Gemcitabine / Cisplatin or 3) Gemcitabine / Carboplatin or 4) Ramucirumab/Paclitaxel or&#xD;
      5) PD1 inhibitors (Nivolumab or Pembrolizumab) or 6) Imiquimod Cream for subcutaneous lesions&#xD;
      7) Bevacizumab 8) Gemcitabine / Carboplatin / Bevacizumab, 9) Topotecan, or 10) PLD in&#xD;
      Patients with Selected Advanced Solid Tumors. The objectives of this study are to determine&#xD;
      the safety, tolerability, MTD, recommended Phase 2 dose (RP2D), PK, and preliminary&#xD;
      anti-tumor activity of TRK-950 when used in combination with other treatment regimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>bpm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>bpm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>°F or °C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>lbs/kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>inches/cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance status using Karnofsky performance status criteria</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>QTc interval determined from 12-lead Electrocardiogram</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>msec</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QRS interval determined from 12-lead Electrocardiogram</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>msec</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of patients with laboratory abnormalities (Complete Blood Count, Coagulation, Urinalysis and Serum Chemistry)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of TRK-950</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Gemcitabine for the first six patients in Arm K</measure>
    <time_frame>At the beginning of Cycle 1 and Cycle 4 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Carboplatin for the first six patients in Arm K</measure>
    <time_frame>At the beginning of Cycle 1 and Cycle 4 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of Bevacizumab for the first six patients in Arm K</measure>
    <time_frame>At the beginning of Cycle 1, Cycle 2, Cycle 4 and Cycle 5 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Topotecan for the first six patients in Arm M</measure>
    <time_frame>At the beginning of Cycle 1 and Cycle 3 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of PLD for the first six patients in Arm O</measure>
    <time_frame>At the beginning and middle of Cycle 1 and Cycle 3 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of Ramucirumab for the first six patients in Arm Q</measure>
    <time_frame>At the beginning and middle of Cycle 1 and Cycle 4 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Paclitaxel for the first six patients in Arm Q</measure>
    <time_frame>At the beginning of Cycle 1 and Cycle 4 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Bladder Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Palpable Subcutaneous Malignant Lesions</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: TRK-950 + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colorectal Cancer&#xD;
TRK-950 will be administered intravenously (IV) on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: TRK-950 + Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholangiocarcinoma or Bladder Cancer&#xD;
TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Cisplatin will be administered by infusion. Then, Gemcitabine will be administered as an IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: TRK-950 + Gemcitabine/Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovarian Cancer&#xD;
TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Gemcitabine will be administered as an intravenous infusion. On day 1, following the administration of TRK-950 and Gemcitabine, Carboplatin will be administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: TRK-950 + Ramucirumab/Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric Cancer&#xD;
TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Ramucirumab will be administered as an IV infusion. Paclitaxel will be dosed on days 1, 8 and 15, after the Ramucirumab on days 1 and 15 and after the TRK-950 on day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: TRK-950 + PD1 inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•Solid Tumors&#xD;
E-1: TRK-950 + Nivolumab&#xD;
•TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.&#xD;
E-2: TRK-950 + Pembrolizumab&#xD;
•TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F: TRK-950 + Imiquimod Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palpable subcutaneous malignant lesions&#xD;
TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. Imiquimod cream is to be applied 5 of 7 days in a row with 2 days rest for a maximum of 2 cycles (total 6 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G: TRK-950 + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Cell Carcinoma&#xD;
TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Bevacizumab will be administered as an IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H: TRK-950 + PD1 inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•Melanoma&#xD;
H-1: TRK-950 + Nivolumab&#xD;
•TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.&#xD;
H-2: TRK-950 + Pembrolizumab&#xD;
•TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J: TRK-950 + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colorectal Cancer&#xD;
TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm K: TRK-950(Lower-dose) + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer&#xD;
TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. Gemcitabine will be administered as an intravenous infusion on days 1 and 8. On day 1, following the administration of Gemcitabine, Carboplatin will be administered as an intravenous infusion. Also on Day 1 of each cycle, Bevacizumab will be administered IV next. After 6 cycles of chemotherapy the patient will be transitioned to maintenance treatment. On Day 1 of each maintenance cycle, Bevacizumab will be administered IV. Maintenance treatment will be continued as long as there is no evidence of progressive disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm L: TRK-950 + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer&#xD;
TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. Gemcitabine will be administered as an intravenous infusion on days 1 and 8. On day 1, following the administration of Gemcitabine, Carboplatin will be administered as an intravenous infusion. Also on Day 1 of each cycle, Bevacizumab will be administered IV next. After 6 cycles of chemotherapy the patient will be transitioned to maintenance treatment. On Day 1 of each maintenance cycle, Bevacizumab will be administered IV. Maintenance treatment will be continued as long as there is no evidence of progressive disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm M: TRK-950(Lower-dose) + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer&#xD;
TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. Topotecan will be administered as an intravenous infusion daily for 5 consecutive days of a 21 day cycle. On day 1 TRK-950 will be administered IV after the topotecan infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm O: TRK-950(Lower-dose) + PLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer&#xD;
TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. PLD will be dosed as IV on Day 1 of each cycle. On days that TRK-950 and PLD are both dosed, PLD will be dosed first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Q: TRK-950(Lower-dose) +Ramucirumab/Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric cancer&#xD;
TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. On days 1 and 15, ramucirumab will be administered IV. Paclitaxel will be dosed on days 1, 8 and 15, after ramucirumab on days 1 and 15, before TRK-950 on day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TRK-950</intervention_name>
    <description>Intravenously over 60 minutes</description>
    <arm_group_label>Arm A: TRK-950 + FOLFIRI</arm_group_label>
    <arm_group_label>Arm B: TRK-950 + Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_label>Arm C: TRK-950 + Gemcitabine/Carboplatin</arm_group_label>
    <arm_group_label>Arm D: TRK-950 + Ramucirumab/Paclitaxel</arm_group_label>
    <arm_group_label>Arm E: TRK-950 + PD1 inhibitors</arm_group_label>
    <arm_group_label>Arm F: TRK-950 + Imiquimod Cream</arm_group_label>
    <arm_group_label>Arm G: TRK-950 + Bevacizumab</arm_group_label>
    <arm_group_label>Arm H: TRK-950 + PD1 inhibitors</arm_group_label>
    <arm_group_label>Arm J: TRK-950 + FOLFIRI</arm_group_label>
    <arm_group_label>Arm K: TRK-950(Lower-dose) + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
    <arm_group_label>Arm L: TRK-950 + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
    <arm_group_label>Arm M: TRK-950(Lower-dose) + Topotecan</arm_group_label>
    <arm_group_label>Arm O: TRK-950(Lower-dose) + PLD</arm_group_label>
    <arm_group_label>Arm Q: TRK-950(Lower-dose) +Ramucirumab/Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Intravenously over 30 - 90 minutes</description>
    <arm_group_label>Arm A: TRK-950 + FOLFIRI</arm_group_label>
    <arm_group_label>Arm J: TRK-950 + FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Intravenously over 30 - 90 minutes</description>
    <arm_group_label>Arm A: TRK-950 + FOLFIRI</arm_group_label>
    <arm_group_label>Arm J: TRK-950 + FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Intravenously bolus and intravenously for two days</description>
    <arm_group_label>Arm A: TRK-950 + FOLFIRI</arm_group_label>
    <arm_group_label>Arm J: TRK-950 + FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenously over 30 minutes</description>
    <arm_group_label>Arm B: TRK-950 + Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_label>Arm C: TRK-950 + Gemcitabine/Carboplatin</arm_group_label>
    <arm_group_label>Arm K: TRK-950(Lower-dose) + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
    <arm_group_label>Arm L: TRK-950 + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Intravenously over 60 minutes</description>
    <arm_group_label>Arm B: TRK-950 + Gemcitabine/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intravenously per package insert</description>
    <arm_group_label>Arm C: TRK-950 + Gemcitabine/Carboplatin</arm_group_label>
    <arm_group_label>Arm K: TRK-950(Lower-dose) + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
    <arm_group_label>Arm L: TRK-950 + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Intravenously over 60 minutes</description>
    <arm_group_label>Arm D: TRK-950 + Ramucirumab/Paclitaxel</arm_group_label>
    <arm_group_label>Arm Q: TRK-950(Lower-dose) +Ramucirumab/Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenously</description>
    <arm_group_label>Arm D: TRK-950 + Ramucirumab/Paclitaxel</arm_group_label>
    <arm_group_label>Arm Q: TRK-950(Lower-dose) +Ramucirumab/Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Intravenously over 30 minutes</description>
    <arm_group_label>Arm E: TRK-950 + PD1 inhibitors</arm_group_label>
    <arm_group_label>Arm H: TRK-950 + PD1 inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Intravenously over 30 minutes</description>
    <arm_group_label>Arm E: TRK-950 + PD1 inhibitors</arm_group_label>
    <arm_group_label>Arm H: TRK-950 + PD1 inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod Cream</intervention_name>
    <description>Topically</description>
    <arm_group_label>Arm F: TRK-950 + Imiquimod Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses</description>
    <arm_group_label>Arm G: TRK-950 + Bevacizumab</arm_group_label>
    <arm_group_label>Arm K: TRK-950(Lower-dose) + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
    <arm_group_label>Arm L: TRK-950 + Gemcitabine / Carboplatin / Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Intravenously over 30 minutes</description>
    <arm_group_label>Arm M: TRK-950(Lower-dose) + Topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD</intervention_name>
    <description>Intravenously over 60 minutes</description>
    <arm_group_label>Arm O: TRK-950(Lower-dose) + PLD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid malignancy for which the following treatment regimens&#xD;
             are warranted:&#xD;
&#xD;
          -  Arm A. Colorectal Cancer with no prior history of treatment with Irinotecan alone or&#xD;
             in combination: FOLFIRI as standard of care&#xD;
&#xD;
          -  Arm B. Cholangiocarcinoma, Bladder Cancer with no prior history of treatment with&#xD;
             Gemcitabine alone or in combination: Gemcitabine / Cisplatin as standard of care&#xD;
&#xD;
          -  Arm C and Expansion Cohort 1. Ovarian Cancer who have relapsed at least 6 or more&#xD;
             months after completion of a previous platinum-based therapy and have no prior history&#xD;
             of treatment with gemcitabine alone or in combination: Gemcitabine / Carboplatin as&#xD;
             standard of care&#xD;
&#xD;
          -  Arm D and Expansion Cohort 2. Gastric Cancer including Gastroesophageal Junction with&#xD;
             no prior history of treatment with Ramucirumab, Paclitaxel or any Taxane class drug:&#xD;
             Ramucirumab / Paclitaxel as standard of care&#xD;
&#xD;
          -  Arm E. Solid Tumors: Eligible for PD1 Inhibitor (Nivolumab or Pembrolizumab)&#xD;
             monotherapy as standard of care according to the approved drug label by the relevant&#xD;
             regulatory authority&#xD;
&#xD;
          -  Arm F. Locally advanced or metastatic disease in a cancer with at least one palpable&#xD;
             subcutaneous malignant lesion(≤ 2 cm in diameter) for treatment with TRK-950 and&#xD;
             Imiquimod cream (US Sites Only)&#xD;
&#xD;
          -  Arm G. Renal Cell Carcinoma with no prior history of treatment with Bevacizumab alone&#xD;
             or in combination: Bevacizumab for use in a fourth line or later treatment&#xD;
&#xD;
          -  Arm H. Melanoma patients who progressed while taking Nivolumab, Pembrolizumab, or&#xD;
             Ipilimumab, within the last 6 months prior to cycle 1 day 1&#xD;
&#xD;
          -  Arm J. Colorectal Cancer patients who progressed on FOLFIRI or any other&#xD;
             Irinotecan-containing therapy regimen within the last 6 months prior to cycle 1 day 1&#xD;
&#xD;
          -  Arm K(US Sites Only). Platinum Sensitive epithelial ovarian, primary peritoneal or&#xD;
             fallopian tube cancer with ≤ 2 prior treatment lines who have recurred &gt; 6 months&#xD;
             after most recent platinum-based chemotherapy and who are eligible for gemcitabine,&#xD;
             carboplatin, and Bevacizumab as standard of care for dosing of TRK-950(Lower-dose)&#xD;
&#xD;
          -  Arm L(US Sites Only). Platinum Sensitive epithelial ovarian, primary peritoneal or&#xD;
             fallopian tube cancer with ≤ 2 prior treatment lines who have recurred &gt; 6 months&#xD;
             after most recent platinum-based chemotherapy and who are eligible for gemcitabine,&#xD;
             carboplatin, and Bevacizumab as standard of care for dosing of TRK-950&#xD;
&#xD;
          -  Arm M. Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube&#xD;
             cancer with ≤ 5 prior treatment regimens, who have recurred ≤ 6 months after most&#xD;
             recent platinum-based chemotherapy and who are eligible for topotecan as standard of&#xD;
             care for dosing of TRK-950(Lower-dose)&#xD;
&#xD;
          -  Arm O. Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube&#xD;
             cancer with ≤ 5 prior treatment regimens, who have recurred ≤ 6 months after most&#xD;
             recent platinum-based chemotherapy and who are eligible for pegylated liposomal&#xD;
             doxorubicin as standard of care for dosing of TRK-950(Lower-dose)&#xD;
&#xD;
          -  Arm Q. Gastric Cancer including GEJ cancer with only 1 prior treatment regimen, which&#xD;
             recurred during or within 4 months after frontline treatment, and no prior history of&#xD;
             treatment with Ramucirumab, Paclitaxel or any Taxane class drug: eligible to receive&#xD;
             Ramucirumab/Paclitaxel as standard of care (Lower-dose)&#xD;
&#xD;
          -  Primary or metastatic tumors measurable per RECIST v1.1 on CT scan or by calipers&#xD;
             (subcutaneous lesions)&#xD;
&#xD;
          -  Karnofsky performance of ≥70&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Signed, written IRB-approved informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory values or medications that are contraindicated in the selected standard of&#xD;
             care treatment regimens&#xD;
&#xD;
          -  New York Heart Association Class III or IV, cardiac disease, myocardial infarction&#xD;
             within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy. Prophylactic antibiotics are acceptable.&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Treatment with radiation therapy within 2 weeks, or treatment with surgery,&#xD;
             chemotherapy, immunotherapy, or investigational therapy within four weeks prior to&#xD;
             initiation of study treatment.&#xD;
&#xD;
          -  Unwillingness or inability to comply with procedures required in this protocol&#xD;
&#xD;
          -  Known active infection with HIV, hepatitis B, hepatitis C&#xD;
&#xD;
          -  Serious nonmalignant disease that could compromise protocol objectives in the opinion&#xD;
             of the investigator and/or the sponsor&#xD;
&#xD;
          -  Patients who are currently receiving any other investigational agent&#xD;
&#xD;
          -  Any contraindicated condition or drug which would make the patient ineligible for the&#xD;
             respective treatment regimen that is to be used in combination with TRK-950 (for&#xD;
             example, autoimmune disorders for nivolumab or pembrolizumab treatment) as described&#xD;
             in the Full Prescribing Information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vicki Bauernschub, BSN, RN</last_name>
    <phone>602 358 8324</phone>
    <email>vbauernschub@td2inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN,RN,AOCNS</last_name>
      <phone>480-323-1339</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiomara Menendez, BSN, RN</last_name>
      <phone>323-409-4368</phone>
      <email>Xiomara.Menendez@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOAG Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Nguyen, CCRP</last_name>
      <phone>949-764-6763</phone>
      <email>chi.nguyen@hoag.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Woolery, RN</last_name>
      <email>Amanda.woolery@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Alistar, Dr.</last_name>
      <phone>973-971-7960</phone>
      <email>Angela.Alistar@atlantichealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical College of Wisconsin</last_name>
      <phone>866-680-0505</phone>
      <phone_ext>8900</phone_ext>
      <email>cccto@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Medical College of Wisconsin</last_name>
      <phone>414-805-8900</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Cassier, M.D.</last_name>
      <phone>+33 (0)4 26 55 68 33</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

